Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)
TWD 28.8
(-1.54%)
TWD 28.8
(-1.54%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 264.9 Million TWD | -43.14% |
| 2022 | 465.86 Million TWD | 16.24% |
| 2021 | 400.77 Million TWD | -24.65% |
| 2020 | 531.87 Million TWD | 354.58% |
| 2019 | 117 Million TWD | -50.05% |
| 2018 | 234.25 Million TWD | 173.13% |
| 2017 | 85.76 Million TWD | 42.27% |
| 2016 | 60.28 Million TWD | -80.45% |
| 2015 | 308.35 Million TWD | 2013.19% |
| 2014 | 14.59 Million TWD | -84.93% |
| 2013 | 96.82 Million TWD | -44.85% |
| 2012 | 175.56 Million TWD | 2.67% |
| 2011 | 170.99 Million TWD | -8.56% |
| 2010 | 187 Million TWD | -23.7% |
| 2009 | 245.1 Million TWD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 40.55 Million TWD | -8.3% |
| 2024 Q2 | 21.07 Million TWD | -48.03% |
| 2023 Q1 | 179.24 Million TWD | 157.51% |
| 2023 Q4 | 44.22 Million TWD | 273.74% |
| 2023 Q2 | 29.6 Million TWD | -83.48% |
| 2023 FY | 264.9 Million TWD | -43.14% |
| 2023 Q3 | 11.83 Million TWD | -60.03% |
| 2022 Q1 | 127.66 Million TWD | 39.87% |
| 2022 Q4 | 69.6 Million TWD | -42.33% |
| 2022 Q3 | 120.7 Million TWD | -18.39% |
| 2022 FY | 465.86 Million TWD | 16.24% |
| 2022 Q2 | 147.89 Million TWD | 15.85% |
| 2021 Q2 | 126.32 Million TWD | 28.58% |
| 2021 Q3 | 84.92 Million TWD | -32.77% |
| 2021 FY | 400.77 Million TWD | -24.65% |
| 2021 Q1 | 98.24 Million TWD | -0.31% |
| 2021 Q4 | 91.27 Million TWD | 7.47% |
| 2020 Q4 | 98.55 Million TWD | 186.38% |
| 2020 Q3 | 34.41 Million TWD | -90.73% |
| 2020 Q1 | 27.75 Million TWD | -24.91% |
| 2020 FY | 531.87 Million TWD | 354.58% |
| 2020 Q2 | 371.14 Million TWD | 1237.23% |
| 2019 Q4 | 36.96 Million TWD | 44.97% |
| 2019 FY | 117 Million TWD | -50.05% |
| 2019 Q3 | 25.49 Million TWD | 89.34% |
| 2019 Q2 | 13.46 Million TWD | -67.22% |
| 2019 Q1 | 41.07 Million TWD | 1094.14% |
| 2018 FY | 234.25 Million TWD | 173.13% |
| 2018 Q3 | 219.75 Million TWD | 1369.51% |
| 2018 Q2 | 14.95 Million TWD | 306.58% |
| 2018 Q1 | 3.67 Million TWD | -92.3% |
| 2018 Q4 | -4.13 Million TWD | -101.88% |
| 2017 Q1 | -11.9 Million TWD | -141.48% |
| 2017 Q3 | 62.13 Million TWD | 609.28% |
| 2017 Q2 | -12.2 Million TWD | -2.45% |
| 2017 Q4 | 47.73 Million TWD | -23.17% |
| 2017 FY | 85.76 Million TWD | 42.27% |
| 2016 Q4 | 28.7 Million TWD | 105.93% |
| 2016 Q1 | 17.51 Million TWD | -71.97% |
| 2016 Q3 | 13.94 Million TWD | 11714.41% |
| 2016 FY | 60.28 Million TWD | -80.45% |
| 2016 Q2 | 118 Thousand TWD | -99.33% |
| 2015 Q3 | 32.01 Million TWD | 142.95% |
| 2015 FY | 308.35 Million TWD | 2013.19% |
| 2015 Q1 | 200.66 Million TWD | 51090.05% |
| 2015 Q2 | 13.17 Million TWD | -93.43% |
| 2015 Q4 | 62.49 Million TWD | 95.18% |
| 2014 Q2 | 24.08 Million TWD | 103.89% |
| 2014 Q3 | -21.69 Million TWD | -190.08% |
| 2014 Q1 | 11.81 Million TWD | 312.86% |
| 2014 FY | 14.59 Million TWD | -84.93% |
| 2014 Q4 | 392 Thousand TWD | 101.81% |
| 2013 Q1 | 41.76 Million TWD | 442.6% |
| 2013 FY | 96.82 Million TWD | -44.85% |
| 2013 Q3 | 6.83 Million TWD | -84.94% |
| 2013 Q4 | 2.86 Million TWD | -58.13% |
| 2013 Q2 | 45.36 Million TWD | 8.6% |
| 2012 Q2 | 88.16 Million TWD | 130.89% |
| 2012 FY | 175.56 Million TWD | 2.67% |
| 2012 Q4 | 7.69 Million TWD | -82.13% |
| 2012 Q3 | 43.08 Million TWD | -51.13% |
| 2012 Q1 | 38.18 Million TWD | -10.65% |
| 2011 Q2 | 37.25 Million TWD | -16.22% |
| 2011 Q1 | 44.46 Million TWD | -25.22% |
| 2011 Q3 | 46.54 Million TWD | 24.95% |
| 2011 FY | 170.99 Million TWD | -8.56% |
| 2011 Q4 | 42.73 Million TWD | -8.19% |
| 2010 Q1 | 37.27 Million TWD | 0.0% |
| 2010 FY | 187 Million TWD | -23.7% |
| 2010 Q2 | 41.97 Million TWD | 12.6% |
| 2010 Q4 | 59.46 Million TWD | 23.12% |
| 2010 Q3 | 48.29 Million TWD | 15.06% |
| 2009 FY | 245.1 Million TWD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Apex Biotechnology Corp. | 115.78 Million TWD | -128.798% |
| Sinphar Pharmaceutical Co.,Ltd. | 375.17 Million TWD | 29.39% |
| Panion & Bf Biotech Inc. | 77.21 Million TWD | -243.062% |
| GenMont Biotech Incorporation | 32.99 Million TWD | -702.974% |
| Abnova (Taiwan) Corporation | 43.67 Million TWD | -506.504% |
| Adimmune Corporation | -639.89 Million TWD | 141.399% |
| Tanvex BioPharma, Inc. | -2.13 Billion TWD | 112.396% |
| Polaris Group | -1.57 Billion TWD | 116.802% |
| Energenesis Biomedical CO.,LTD. | -260.38 Million TWD | 201.739% |
| UnicoCell Biomed Co., Ltd. | -84.1 Million TWD | 414.963% |
| PELL Bio-Med Technology Co. Ltd. | -398.75 Million TWD | 166.434% |